Phase 2 Trial of Difelikefalin in Notalgia Paresthetica.

Brian S KimRobert BissonnetteKristine NogralesCatherine MuneraNilam ShahAlia JebaraJoshua CirulliJoana GoncalvesMark Lebwohlnull null

Published in: The New England journal of medicine (2023)

Among patients with notalgia paresthetica, oral treatment with difelikefalin resulted in modestly greater reductions in itch intensity scores than placebo over a period of 8 weeks but was associated with adverse events. Larger and longer trials are needed to assess the efficacy and safety of difelikefalin treatment in this disorder. (Funded by Cara Therapeutics; KOMFORT ClinicalTrials.gov number, NCT04706975.).

Keyphrases

small molecule
replacement therapy
double blind
gestational age
smoking cessation
phase iii